Larimar Therapeutics, Inc.
LRMR
$0.03
Change (1 day)
$13.68
Year High
$3.01
Year Low
Categories
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics, Inc. (LRMR) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -21,203,000 | 14.22 M | 95.94 M | 90.18 M | |
| 2022 | -21,417,000 | 15.5 M | 126.41 M | 120.74 M | |
| 2021 | 208 K | -64,095,000 | 14.25 M | 78.67 M | 72.2 M |
| 2020 | 32 K | -61,631,000 | 14.99 M | 104.69 M | 97.95 M |
| 2019 | -912,000 | 5.9 M | 5.2 M | 4.75 M |